Tomorrow I’ll present a poster on this tri-specific T-cell engager made by Harpoon. It’s a DLL3 specific, tri-specific that also binds to T-cells, stimulates the T-cells and introduces them into the tumor.
So we’ve treated about three different dose levels. We have had a couple partial responses and some other patients with target lesion shrinkage, and so the dose escalation continues...
Tomorrow I’ll present a poster on this tri-specific T-cell engager made by Harpoon. It’s a DLL3 specific, tri-specific that also binds to T-cells, stimulates the T-cells and introduces them into the tumor.
So we’ve treated about three different dose levels. We have had a couple partial responses and some other patients with target lesion shrinkage, and so the dose escalation continues. It’s been well tolerated with manageable cytokine release.